Results 251 to 260 of about 1,010,901 (298)

Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

NEJM Evidence, 2023
BACKGROUND: EMBARK, a controlled trial reported elsewhere, showed enzalutamide plus leuprolide (combination) and enzalutamide monotherapy prolonged metastasis-free survival versus placebo plus leuprolide (alone) in patients with high-risk biochemically recurrent prostate cancer. Health-related quality of life was also analyzed but not reported. METHODS:
Stephen J, Freedland, Martin, Gleave, Ugo, De Giorgi, Antti, Rannikko, Christopher M, Pieczonka, Ronald F, Tutrone, Balaji, Venugopal, Henry H, Woo, Miguel, Ramirez-Backhaus, Stephane, Supiot, Anna, Lantz, Arijit, Ganguli, Jasmina, Ivanova, Pavol, Kral, Shu-Pin, Huang, Fred, Saad, Neal D, Shore   +16 more
openaire   +2 more sources

Management Options for Biochemically Recurrent Prostate Cancer

Current Treatment Options in Oncology, 2017
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging.
Farhad, Fakhrejahani, Ravi A, Madan, William L, Dahut   +2 more
openaire   +2 more sources

Physiological and biochemical responses of clams to recurrent marine heatwaves

Marine Environmental Research, 2023
In the past decade, the frequency, intensity and duration of marine heatwaves (MHWs) in the South China Sea have been increasing strikingly, resulting in serious impacts on intertidal bivalves and their ecosystems. The Manila clam, Ruditapes philippinarum, is one of the most ecologically and economically important bivalve species in the South China Sea,
Ke, Yang, Yang, Xu, Guixiang, He, Xiaolong, Liu, Yong, Liu, Liqiang, Zhao   +5 more
openaire   +2 more sources

Characterization of Biochemical Recurrence after Radical Prostatectomy

Urologia Internationalis, 2006
<i>Background:</i> This study sought to characterize the variables that predict postoperative prostate-specific antigen doubling time (PSADT) and biochemical recurrence time (RT) in patients who have failed radical prostatectomy (RP).
Joseph, Molitierno, Aubrey, Evans, James L, Mohler, Eric, Wallen, Dominic, Moore, Raj S, Pruthi   +5 more
openaire   +2 more sources

Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis

Journal of Clinical Microbiology, 1992
Because so little is known about the pathogenesis of recurrent bacterial vaginosis (BV), a longitudinal microbiological study was conducted on 13 women with recurrent BV treated sequentially with conventional metronidazole therapy. A rapid clinical response characterized by disappearance of mal odor and an improvement in vaginal discharge occurred in ...
R L, Cook, V, Redondo-Lopez, C, Schmitt, C, Meriwether, J D, Sobel   +4 more
openaire   +2 more sources

Biochemical Recurrence after Localized Treatment

Urologic Clinics of North America, 2006
The quoted incidence of biochemical recurrence (BCR) after localized treatment varies significantly and depends on numerous well-known prognostic factors; however, it likely occurs in at least 30%-40% of patients who receive localized treatment. Because the clinical significance of BCR is often unclear, and depends in many cases on unknown factors, it ...
openaire   +2 more sources

Biochemically recurrent prostate cancer: rationalisation of the approach to imaging

Clinical Radiology, 2023
To assess the utility of magnetic resonance imaging (MRI) in addition to the additive benefit of the conventional imaging techniques, computed tomography (CT) and nuclear medicine (NM) bone scintigraphy, for investigation of biochemical recurrence (BCR) post-prostatectomy where access to prostate specific membrane antigen (PSMA) positron-emission ...
H, Briody, M, Sheehan, M, Hanley, B, O'Neill, R, Dunne, M J, Lee, M M, Morrin   +6 more
openaire   +2 more sources

Biochemical Recurrence after Radical Prostatectomy

DeckerMed Urology, 2018
After receiving local treatment, many patients will develop a biochemical recurrence (BCR) in the absence of detectable distant disease (cM0) and comprise a significant proportion (20.1%) of prostate cancer disease states. The natural history of patients with BCR ranges from those with indolent, nonprogressive, slow prostate-specific antigen (PSA)-only
Brian Chapin, Scott Delacroix, Dunia Khaled   +2 more
openaire   +1 more source

Immunotherapy for biochemically recurrent prostate cancer.

Journal of Clinical Oncology, 2018
215 Background: Annually about 30-50,000 men are diagnosed with biochemically recurrent prostate cancer (BCRpc), defined by a rising PSA after radical prostatectomy (RP) or definitive radiation therapy (RT) with negative conventional imaging (CT and bone scan). Standard treatments include salvage therapies, androgen deprivation or surveillance.
Ravi Amrit Madan, Fatima Karzai, Marijo Bilusic, Julius Strauss, Susan F. Slovin, Lauren Christine Harshman, Marc Robert Theoret, Philip M. Arlen, Myrna Rauckhorst, Anna Couvillon, Amy Hankin, Monique Williams, Philip W. Kantoff, William L. Dahut, Jeffrey Schlom, James L. Gulley   +15 more
openaire   +1 more source

Updates on Management of Biochemical Recurrent Prostate Cancer

Current Treatment Options in Oncology
Patients with biochemical recurrent prostate cancer (BCR) are a heterogeneous group, whereby a personalized approach to management is critical. Patients with high-risk features such as PSA doubling time (PSADT) ≤ 9-12 months warrant earlier imaging for metastasis detection and consideration for intensified therapy (beyond intermittent androgen ...
Lauren Folgosa, Cooley, Abhishek, Srivastava, Neal D, Shore   +2 more
openaire   +2 more sources